Navigation Links
Team finds promising new drug target for Alzheimer's disease
Date:4/20/2010

hers found, amyloid-beta binds to a different part of the receptor than that normally engaged by neurotransmitters and hormones. This means it may be possible to stop amyloid-beta from binding to it without hindering the other functions of the beta-2 adrenergic receptor.

Previous studies have shown that Alzheimer's patients who also take beta-blockers tend to see a slower decline in their mental function. These drugs are meant to treat hypertension and other conditions by targeting beta-adrenergic receptors, including beta-2. This finding provides further support to the idea that the beta-2 adrenergic receptor is a key to the ill effects of Alzheimer's disease.

Xiang and Cox stress that the beta-2 adrenergic receptor is almost certainly not the only important player in the damage that occurs in an Alzheimer's-afflicted brain. But they see it as a promising new potential target for future drug research.


'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Given No Chance to Survive with Pancreatic Cancer, Chicago Woman Finds New Life at Northwest Community Hospital
2. Study finds treatment-resistant ringworm prevalent among children in metro elementary schools
3. Convenience drives US women to buy over-the-counter contraception in Mexico, study finds
4. Dance therapy improves seniors gait, balance, researcher finds
5. The Medical Marijuana Industry Finds an Outside-the-Box Solution, "Inside the Box" With GrowOp Technology
6. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
7. Study finds changes in fetal epigenetics throughout pregnancy
8. Statins may slow progression of multiple sclerosis, new study finds
9. Study Finds Military Prone to Infection With H1N1 Flu
10. Eating disorder cutoffs miss some of sickest patients, Stanford/Packard study finds
11. UBC graduate student finds a start/stop switch for retroviruses
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Team finds promising new drug target for Alzheimer's disease
(Date:7/23/2014)... (PRWEB) July 23, 2014 As the body ... more slowly resulting in old muscle being replaced by fatty ... excess fat in the belly region, the most dangerous area ... fat, actually surrounds the internal organs and circulates through the ... related conditions. , For this reason, Diet Doc’s staff ...
(Date:7/23/2014)... Raleigh, NC (PRWEB) July 23, 2014 ... is chemically similar to the yellow pigment in the ... destroy mesothelioma cells in the lab. To read ... , Scientists at Gazi University in Ankara, Turkey ... with both compounds before exposing them to two platinum-based ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... some state-run insurance exchanges to come up with ... some of the myriad ways to accomplish this ... Services’s Inside Health Insurance Exchanges (HEX). , “We ... high” for state-run exchanges, Christopher Condeluci, an attorney ...
(Date:7/23/2014)... On July 19 and 20, the HearStrong Foundation ... and New York Giants Health & Fitness Expo 2014 at ... team, which included several hearing healthcare providers affiliated with ... and answered any questions that attendees had about their hearing ... sponsored by the NFL Players Association, HearStrong was proud to ...
(Date:7/23/2014)... Seattle, Wa (PRWEB) July 23, 2014 ... body sweats, it means that it is healthy enough ... is also useful for “washing out” harmful toxins and ... excretory system of the body just cannot do. ... prone to hyperhidrosis—or more commonly known as “excessive sweating”—are ...
Breaking Medicine News(10 mins):Health News:Diet Doc Medical Weight Loss Programs Announces Exclusive Diet Plans for Men that are Simple, Easy to Follow and Melt Dangerous Belly Fat 2Health News:Diet Doc Medical Weight Loss Programs Announces Exclusive Diet Plans for Men that are Simple, Easy to Follow and Melt Dangerous Belly Fat 3Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 3Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:The HearStrong Foundation Provides Hearing Healthcare Awareness at the NBC 4 New York and New York Giants Health & Fitness Expo 2014 2Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 2Health News:Beat Your Sweating Demons Review | The Problem With Excessive Sweating and Solving it Naturally – Vinamy.com 3
... 18 /PRNewswire-Asia-FirstCall/ -- China YCT International,Group Inc., (OTC ... a,leading company engaged in the business of developing, ... subsidiary, Shandong,Spring Pharmaceutical Co. Ltd, today announced its ... December 31, 2008. , , ...
... Professional Athletes Who Use the OmniPod System to Manage their ... of the country,s top professional cross-country skiers, is competing on ... month. As a world-class athlete, Freeman intends to medal, ... I diabetes. Diabetes doesn,t keep Freeman from performing at ...
... Innovations in the Past 30 Years - Quantros President and Chief ... last week, discussing the importance of using technology to track and ... , ... San Francisco, CA (PRWEB) February 17, 2009 - ...
... International Effort to Combat Rare Diseases That Collectively Effect 1 in 10 ... ... 2009 -- Students at Albany High School in Albany, California, are asking ... support the first annual World Rare Disease Day, an international event being ...
... Growth is expected in Australian pharmaceuticals and ... accounted for 80 percent or $258.6 million and will continue ... same period, life sciences spending on IT accounted for $64.6 ... pharmaceuticals and life sciences market. It is expected to ...
... based Renaissance Laser & Vein Institute eliminates varicose ... OAKS, Calif., Feb. 17 Southern California based ... easy and effective method for eliminating painful and ... proper vein structure is a common problem. ...
Cached Medicine News:Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 2Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 3Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 4Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 5Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 6Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 7Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 8Health News:China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results 9Health News:Elite Skier Uses OmniPod(R) Insulin Management System at World Championships 2Health News:Quantros President Appears on National TV Promoting Patient Safety 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing 2Health News:Renaissance Laser & Vein Institute (LaserandVeinclinic.com) Provides Top Notch 'Varicose Vein Treatment' 2
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: